UCLA研究识别驱动癌症免疫治疗T细胞耗竭的关键通路CRL5
Researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy
UCLA Health Jonsson综合癌症中心团队通过CRISPR筛选发现Cullin-5 RING E3连接酶复合物(CRL5)通路驱动T细胞耗竭,在模拟慢性肿瘤暴露的反复刺激模型中抑制该通路可让工程T细胞在临床前模型里更持久、抗耗竭,并改善人黑色素瘤小鼠模型的肿瘤控制。
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center used a CRISPR screen to identify a key molecular pathway that drives exhaustion in cancer-fighting immune cells, limiting their ability to keep tumors under control.
In the study published in the journal Cancer Immunology Research, investigators found that blocking the pathway, known as the Cullin-5 RING E3 ligase complex (CRL5), allowed engineered immune cells to stay active longer, produce stronger antitumor responses and resist exhaustion in preclinical models.
The discovery could help researchers develop longer-lasting immunotherapies for solid tumors, including CAR T-cell therapies and other forms of adoptive cell therapy.
T-cell exhaustion limits lasting tumor control
T-cell exhaustion is one of the main reasons many immunotherapies stop working or fail to produce lasting responses. T cells are the immune system's primary cancer-fighting cells, but in many cancers they are exposed to tumor signals for long periods, gradually losing their ability to effectively attack cancer.
This T-cell exhaustion is especially problematic in solid tumors, where therapies such as CAR-T cells, tumor-infiltrating lymphocyte therapies and T-cell receptor-engineered therapies often struggle to remain effective over time.
"Immunotherapy depends on T cells staying active long enough to continuously recognize and kill cancer cells," said Justin Saco, a graduate student in the laboratory of Dr. Antoni Ribas at UCLA and first author of the study. "If they lose function too early, tumors can grow back or escape immune control. The longer T cells remain functional, the better the chance of durable cancer control."
Screening genes under repeated tumor exposure
To identify the genes involved in T-cell exhaustion, the UCLA team used a genome-wide CRISPR screen in human CD8⁺ T cells engineered to recognize a melanoma antigen. The researchers systematically turned off thousands of genes and repeatedly exposed the CD8⁺ T cells to tumor cells in a laboratory system designed to mimic the chronic tumor exposure seen in patients with solid tumors.
"One unique aspect of the study was the repeated tumor rechallenge system," said Saco. "Instead of studying short-term T-cell activation, we modeled the chronic, repeated tumor exposure that T cells experience in solid tumors. That allowed us to identify regulators of long-term persistence and exhaustion more effectively."
The researchers then analyzed which genetic changes helped T cells stay functional, active and capable of killing cancer cells during repeated tumor exposure.
Blocking CRL5 preserves cancer-fighting function
The screening process revealed a strong and consistent signal pointing to CRL5, a protein-regulating pathway that helps control how cells break down and recycle proteins. It was not just a single gene that stood out. Several different components of the CRL5 machinery were independently enriched across experiments and time points, a pattern that often suggests a biologically important pathway.
When researchers disrupted CRL5-related genes, the modified T cells maintained stronger tumor-killing ability, produced higher levels of immune signaling molecules, showed fewer molecular signs of exhaustion and preserved gene programs linked to survival and long-term immune function.
The team also tested a drug called MLN4924, which blocks activation of Cullin-RING ligases, including CRL5. The drug partially reproduced the effects seen with genetic deletion, helping T cells maintain stronger long-term function in laboratory experiments. In mouse models of human melanoma, animals treated with CRL5-deficient T cells showed improved tumor control compared with those receiving standard engineered immune cells.
Potential for more durable solid-tumor immunotherapies
The findings suggest that targeting the CRL5 pathway could help improve the durability and effectiveness of T-cell–based immunotherapies for patients with solid tumors. By reducing a key biological mechanism that drives T-cell exhaustion, it may be possible to help immune cells stay active longer and maintain their cancer-fighting ability, potentially leading to stronger and more sustained treatment responses.
A companion research article in the same journal by the research group of Dr. Julia Carnevale of UCSF provides additional support for the findings and the potential for targeting molecular mechanisms of T-cell exhaustion to improve cancer immunotherapy.
More information
Justin D. Saco et al., Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation, Cancer Immunology Research (2026). DOI: 10.1158/2326-6066.cir-26-0181
Stefanie Bachl et al., Disruption of the CRL5 ubiquitin ligase complex enhances engineered T-cell persistence under chronic tumor antigen exposure, Cancer Immunology Research (2026). DOI: 10.1158/2326-6066.cir-26-0608
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Alexander Pol
PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →
Citation: Researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy (2026, October 15) retrieved 15 October 2026 from https://medicalxpress.com/news/2026-10-key-pathway-cell-exhaustion-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com